Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study

Ibrutinib treatment has been shown to increase survival in patients with B cell malignancies. Real-life data suggest a large part of discontinuations are due to toxicities, impairing ibrutinib efficacy. We aimed to assess the impact of a pharmaceutical care program on the efficacy and safety of ibru...

Descripción completa

Detalles Bibliográficos
Autores principales: Zerbit, Jeremie, Chevret, Sylvie, Bernard, Sophie, Kroemer, Marie, Ablard, Charlotte, Harel, Stephanie, Brice, Pauline, Madelaine, Isabelle, Thieblemont, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316844/
https://www.ncbi.nlm.nih.gov/pubmed/32483668
http://dx.doi.org/10.1007/s00277-020-04045-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316844/
https://www.ncbi.nlm.nih.gov/pubmed/32483668
http://dx.doi.org/10.1007/s00277-020-04045-y

Ejemplares similares